[Inhaled corticosteroids in patients with COPD: maintain current guidelines]

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Trials

Context:

• Inhaled corticosteroids (ICS) are a debated treatment for Chronic Obstructive Pulmonary Disease (COPD).
• Previous studies suggest ICS, with or without long-acting beta-2-adrenergics (LABA), may reduce exacerbations and improve health status in severe COPD.
• The impact of ICS on COPD patient survival remains unclear.

Purpose:

• To evaluate the efficacy of salmeterol and fluticasone combination therapy versus placebo, salmeterol alone, or fluticasone alone in severe COPD patients.
• To assess the effect of the combination therapy on mortality, exacerbation rates, and health status.

Summary:

• The TORCH trial, a large double-blind, placebo-controlled study, involved 6112 severe COPD patients over 3 years.
• Combination therapy with salmeterol and fluticasone did not significantly reduce the overall death rate (p = 0.052).
• Exacerbation frequency and health status were improved in the combination therapy group.

Impact:

• The TORCH trial findings do not support a change in current treatment guidelines for inhaled corticosteroids in severe COPD.
• While combination therapy improved exacerbations and health status, the lack of significant mortality reduction limits its impact on survival outcomes.
• Further research may be needed to clarify the long-term survival benefits of ICS/LABA therapy in COPD.